3.12 as those listed in 5.2511 and 5.2522. 3.2 Occurrence of tumor recurrence. 3.3 Non-compliance by a patient with protocol requirement. 3.4 Patient refusal further therapy. 3.5 Patient death. 3.6 Interruption of IFN-α therapy ＞4 weeks